Dec. 2024, Cell Symposia: Chemical biology in drugging the undrugged, Award for top poster presented in session 1　　　　　　　　　　　　　　　
Taiga Hirata;Ryodai Yamamura;Masahiro Sonoshita

Oct. 2024, 第32回日本消化器関連学会週間 JDDW2024, 優秀演題賞　　　　　　　　　　　　　　　
青山慶哉;山村凌大;野村朝子;福島新弥;桂田武彦;福田真嗣;園下将大;坂本直哉

Aug. 2024, Hokkaido University, 2024 HU Researcher Overseas Travel Grant Program　　　　　　　　　　　　　　　

Mar. 2024, Serendipity Symposium 2024, Serendipity Challenger Award　　　　　　　　　　　　　　　
Soichiro Hata;Seiichiro Ishihara;Ryodai Yamamura;Hisashi Haga;Masahiro Sonoshita

Jun. 2023, 公益財団法人伊藤医薬学学術交流財団, 海外交流助成　　　　　　　　　　　　　　　

May 2022, 北海道大学遺伝子病制御研究所, 東市郎基金　　　　　　　　　　　　　　　

May 2020, 北海道大学遺伝子病制御研究所, 東市郎基金　　　　　　　　　　　　　　　

Nov. 2017, 第3回COI2021会議, 科学技術振興機構理事長賞　　　　　　　　　　　　　　　

Nov. 2017, 第二回COI若手連携研究会, ベストプレゼンター賞　　　　　　　　　　　　　　　

Jul. 2015, The 2nd FHS International Conference, Best Presentation Award　　　　　　　　　　　　　　　

Assessment of factors associated with antipsychotic-induced weight gain: A nationwide cohort study
Shuhei Ishikawa, Naoki Hashimoto, Ryo Okubo, Ryo Sawagashira, Ryodai Yamamura, Yoichi M. Ito, Norihiro Sato, Ichiro Kusumi
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 111231, 111231, Elsevier BV, Dec. 2024, [Peer-reviewed]
English, Scientific journal

Flow zoometry of Drosophila
Walker Peterson, Joshua Arenson, Soichiro Hata, Laura Kacenauskaite, Tsubasa Kobayashi, Takuya Otsuka, Hanqing Wang, Yayoi Wada, Kotaro Hiramatsu, Zhikai He, Jean-Emmanuel Clement, Chenqi Zhang, Chenglang Hu, Phillip McCann, Hayato Kanazawa, Yuzuki Nagasaka, Hiroyuki Uechi, Yuh Watanabe, Ryodai Yamamura, Mika Hayashi, Yuta Nakagawa, Kangrui Huang, Hiroshi Kanno, Yuqi Zhou, Tianben Ding, Maik Herbig, Shimpei Makino, Shunta Nonaga, Ryosuke Takami, Oguz Kanca, Koji Tabata, Satoshi Amaya, Kotaro Furusawa, Kenichi Ishii, Kazuo Emoto, Fumihito Arai, Ross Cagan, Dino Di Carlo, Tatsushi Igaki, Erina Kuranaga, Shinya Yamamoto, Hugo J Bellen, Tamiki Komatsuzaki, Masahiro Sonoshita, Keisuke Goda
bioRxiv, Cold Spring Harbor Laboratory, 05 Apr. 2024
English, Scientific journal, ABSTRACT

Drosophilaserves as a highly valuable model organism across numerous fields including genetics, immunology, neuroscience, cancer biology, and developmental biology. Central toDrosophila-based biological research is the ability to perform comprehensive genetic or chemical screens. However, this research is often limited by its dependence on laborious manual handling and analysis, making it prone to human error and difficult to discern statistically significant or rare events amid the noise of individual variations resulting from genetic and environmental factors. In this article we present flow zoometry, a whole-animal equivalent of flow cytometry for large-scale, individual-level, high-content screening ofDrosophila. Our flow zoometer automatically clears the tissues ofDrosophila melanogaster, captures three-dimensional (3D) multi-color fluorescence tomograms of single flies with single-cell volumetric resolution at an unprecedented throughput of over 1,000 animals within 48 hours (24 hr for clearing; 24 hr for imaging), and performs AI-enhanced data-driven analysis – a task that would traditionally take months or years with manual techniques. To demonstrate its broad applications, we employed the flow zoometer in various laborious screening assays, including those in toxicology, genotyping, and tumor screening. Flow zoometry represents a pivotal evolution in high-throughput screening technology: previously from molecules to cells, now from cells to whole animals. This advancement serves as a foundational platform for “statistical spatial biology”, to improve empirical precision and enable serendipitous discoveries across various fields of biology.

膵癌の遺伝子型を模倣したモデルショウジョウバエの活用による膵癌創薬研究の加速　　　　　　　　　　　　　　　
関谷翔, 佐藤伶音, 山村凌大, 園下将大
胆と膵, 45, 2, 127, 134, 15 Feb. 2024
Japanese, Scientific journal

Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma
Junki Fukuda, Shinya Kosuge, Yusuke Satoh, Sho Sekiya, Ryodai Yamamura, Takako Ooshio, Taiga Hirata, Reo Sato, Kanako C. Hatanaka, Tomoko Mitsuhashi, Toru Nakamura, Yoshihiro Matsuno, Yutaka Hatanaka, Satoshi Hirano, Masahiro Sonoshita
Cancer Science, Wiley, 06 Feb. 2024, [Peer-reviewed]
English, Scientific journal, Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies worldwide. However, drug discovery for PDAC treatment has proven complicated, leading to stagnant therapeutic outcomes. Here, we identify Glycogen synthase kinase 3 (GSK3) as a therapeutic target through a whole‐body genetic screening utilizing a ‘4‐hit’ Drosophila model mimicking the PDAC genotype. Reducing the gene dosage of GSK3 in a whole‐body manner or knocking down GSK3 specifically in transformed cells suppressed 4‐hit fly lethality, similar to Mitogen‐activated protein kinase kinase (MEK), the therapeutic target in PDAC we have recently reported. Consistently, a combination of the GSK3 inhibitor CHIR99021 and the MEK inhibitor trametinib suppressed the phosphorylation of Polo‐like kinase 1 (PLK1) as well as the growth of orthotopic human PDAC xenografts in mice. Additionally, reducing PLK1 genetically in 4‐hit flies rescued their lethality. Our results reveal a therapeutic vulnerability in PDAC that offers a treatment opportunity for patients by inhibiting multiple targets.

Efficacy of an eHealth self-management program in reducing irritable bowel syndrome symptom severity: A randomized controlled trial　　　　　　　　　　　　　　　
Jun Tayama, Toyohiro Hamaguchi, Kohei Koizumi, Ryodai Yamamura, Ryo Okubo, Jun-ichiro Kawahara, Kenji Inoue, Atsushi Takeoka, Shin Fukudo
Scientific Reports, 14, 1, 4, Jan. 2024, [Peer-reviewed]
English, Scientific journal

Methylprednisolone pulse enhanced neutrophil extracellular trap formation in mice with imiquimod-induced lupus-like disease, resulting in ischemia of the femoral head cartilage　　　　　　　　　　　　　　　
Hodaka Ogawa, Shunichi Yokota, Yumeka Hosoi, Ayano Shindo, Naho Ogawa, Ryodai Yamamura, Tomohiro Shimizu, Issei Nakade, Suishin Arai, Mai Taniguchi, Yuka Nishibata, Sakiko Masuda, Daigo Nakazawa, Utano Tomaru, Norimasa Iwasaki, Akihiro Ishizu
Lupus Science & Medicine, 10, 2, e001042, Dec. 2023, [Peer-reviewed]
English, Scientific journal

ショウジョウバエを活用した膵がんの創薬研究　　　　　　　　　　　　　　　
小菅 信哉, 平田 大賀, 関谷 翔, 山村 凌大, 園下 将大
BIO Clinica, 2023, 8月号, 16, 20, Aug. 2023, [Invited]
Japanese

Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for Pancreatic Ductal Adenocarcinoma
Sho Sekiya, Junki Fukuda, Ryodai Yamamura, Takako Ooshio, Yusuke Satoh, Shinya Kosuge, Reo Sato, Kanako C. Hatanaka, Yutaka Hatanaka, Tomoko Mitsuhashi, Toru Nakamura, Yoshihiro Matsuno, Satoshi Hirano, Masahiro Sonoshita
Cancer Research, OF1, OF12, American Association for Cancer Research (AACR), 28 Jun. 2023, [Peer-reviewed]
English, Scientific journal, Abstract

Significant progress has been made in understanding the pathogenesis of pancreatic ductal adenocarcinoma (PDAC) by generating and using murine models. To accelerate drug discovery by identifying novel therapeutic targets on a systemic level, here we generated a Drosophila model mimicking the genetic signature in PDAC (KRAS, TP53, CDKN2A, and SMAD4 alterations), which is associated with the worst prognosis in patients. The ‘4-hit’ flies displayed epithelial transformation and decreased survival. Comprehensive genetic screening of their entire kinome revealed kinases including MEK and AURKB as therapeutic targets. Consistently, a combination of the MEK inhibitor trametinib and the AURKB inhibitor BI-831266 suppressed the growth of human PDAC xenografts in mice. In patients with PDAC, the activity of AURKB was associated with poor prognosis. This fly-based platform provides an efficient whole-body approach that complements current methods for identifying therapeutic targets in PDAC.

Significance:

Development of a Drosophila model mimicking genetic alterations in human pancreatic ductal adenocarcinoma provides a tool for genetic screening that identifies MEK and AURKB inhibition as a potential treatment strategy.

短眠はPaneth細胞α-defensin分泌量の低値および短鎖脂肪酸の産生量低下を伴う腸内細菌叢組成の撹乱に関係する
清水 由宇, 山村 凌大, 横井 友樹, 綾部 時芳, 鵜川 重和, 中村 幸志, 岡田 恵美子, 今江 章宏, 中川 貴史, 玉腰 暁子, 中村 公則
腸内細菌学雑誌, 37, 2, 112, 112, (公財)腸内細菌学会, Apr. 2023
Japanese

Shorter sleep time relates to lower human defensin 5 secretion and compositional disturbance of the intestinal microbiota accompanied by decreased short-chain fatty acid production
Yu Shimizu, Ryodai Yamamura, Yuki Yokoi, Tokiyoshi Ayabe, Shigekazu Ukawa, Koshi Nakamura, Emiko Okada, Akihiro Imae, Takafumi Nakagawa, Akiko Tamakoshi, Kiminori Nakamura
Gut Microbes, 15, 1, 2190306, Informa UK Limited, Mar. 2023, [Peer-reviewed]
English, Scientific journal

Intestinal and Fecal pH in Human Health
Ryodai Yamamura, Kumi Y. Inoue, Kunihiko Nishino, Seiji Yamasaki
Frontiers in Microbiomes, 2, Frontiers Media SA, 2023, [Peer-reviewed], [Lead author]
English, Scientific journal, Gut microbiota has been reported to be closely related to host energy metabolism and immunity, and thus influence the development and progression of various human diseases. To date, the gut microbial metabolites such as short-chain fatty acids, defensins, cathelicidins, and lactoferrin in feces have been investigated as biomarkers associated with various disease conditions. In this review, we introduce intestinal and fecal pH, which is relatively easy and rapid to measure compared to the composition of the gut microbiota and its metabolites. In particular, this review presents the distribution of pH in the human body, its role and clinical significance, and various factors that affect intestinal and fecal pH, including the gut microbiota and its metabolites.

Efficacy of a self-management program using an eHealth system to reduce symptom severity in patients with irritable bowel syndrome simultaneously with changes in gut microbiota: a randomized controlled trial
Jun Tayama, Toyohiro Hamaguchi, Kohei Koizumi, Ryodai Yamamura, Ryo Okubo, Jun-ichiro Kawahara, Kenji Inoue, Atsushi Takeoka, Antonius Schneider, Shin Fukudo
medRxiv, Cold Spring Harbor Laboratory, 23 Dec. 2022
English, Scientific journal, ABSTRACT

Objective

This study aimed to evaluate whether a self-management program using the eHealth system could reduce symptom severity in patients with irritable bowel syndrome (IBS). Impact of the intervention on quality of life and gut microbiota were also examined.

Design

This study was designed as an open label, simple randomized controlled trial comparing an intervention group that attended an eHealth self-management program and a treatment as usual group. Participants were Japanese women between the ages of 18 and 36. Forty symptomatic IBS individuals who met the inclusion criteria were recruited and randomly assigned to the two groups. The eHealth group received 8 weeks of unlimited access to the self-management program containing a wide variety of e-learning content. Participants’ severity of IBS symptoms, the main outcome, was assessed using the irritable bowel syndrome-severity index (IBS-SI) at baseline and 8 weeks. The secondary outcomes of participants’ quality of life and gut bacteria were also assessed at baseline and week 8.

Results

There was a significant difference in the net change in IBS severity index (IBS-SI) score between the eHealth and treatment as usual group (−50.1; 95% CI, −87.6 to -12.6; p = 0.010). The eHealth group had significantly lower IBS-SI scores following 8 weeks of intervention compared with the baseline scores (t = − 3.2, p < 0.01). The implementation of the eHealth program was accompanied by improvement of quality of life and decrease of phylum-level Cyanobacteria occupancy, respectively.

Conclusion

The implementation of eHealth for IBS was shown to reduce IBS symptoms.

Key Messages

What is already known on this topic –eHealth programs based on diet and probiotic use have shown good results in reducing IBS symptoms

What this study adds– a self-management program with an e-learning component based on a successful self-help guidebook for IBS

How this study might affect research, practice or policy– The proposed eHealth model reduces symptoms and improves the quality of life of IBS patients, providing an efficient and cost-effective intervention option to be adopted in policy and practice, and creates scope for future research in food intake, exercise, and sleep management through eHealth for IBS.

Drosophila as a toolkit to tackle cancer and its metabolism
Hui Jiang, Taku Kimura, Han Hai, Ryodai Yamamura, Masahiro Sonoshita
Frontiers in Oncology, 12, Frontiers Media SA, Aug. 2022, [Peer-reviewed], [Invited], [Corresponding author]
English, Scientific journal, Cancer is one of the most severe health problems worldwide accounting for the second leading cause of death. Studies have indicated that cancers utilize different metabolic systems as compared with normal cells to produce extra energy and substances required for their survival, which contributes to tumor formation and progression. Recently, the fruit fly Drosophila has been attracting significant attention as a whole-body model for elucidating the cancer mechanisms including metabolism. This tiny organism offers a valuable toolkit with various advantages such as high genetic conservation and similar drug response to mammals. In this review, we introduce flies modeling for cancer patient genotypes which have pinpointed novel therapeutic targets and drug candidates in the salivary gland, thyroid, colon, lung, and brain. Furthermore, we introduce fly models for metabolic diseases such as diabetes mellitus, obesity, and cachexia. Diabetes mellitus and obesity are widely acknowledged risk factors for cancer, while cachexia is a cancer-related metabolic condition. In addition, we specifically focus on two cancer metabolic alterations: the Warburg effect and redox metabolism. Indeed, flies proved useful to reveal the relationship between these metabolic changes and cancer. Such accumulating achievements indicate that Drosophila offers an efficient platform to clarify the mechanisms of cancer as a systemic disease.

高齢者におけるPaneth細胞α-defensin分泌量の低さは加齢に伴う腸内細菌叢の遷移に関連する
清水 由宇, 中村 公則, 菊池 摩仁, 鵜川 重和, 中村 幸志, 岡田 恵美子, 今江 章宏, 中川 貴史, 山村 凌大, 玉腰 暁子, 綾部 時芳
腸内細菌学雑誌, 36, 2, 106, 106, (公財)腸内細菌学会, Apr. 2022
Japanese

Subthreshold change in glycated hemoglobin and body mass index after the initiation of second-generation antipsychotics among patients with schizophrenia or bipolar disorder: A nationwide prospective cohort study in Japan
Ryo Sawagashira, Ryodai Yamamura, Ryo Okubo, Naoki Hashimoto, Shuhei Ishikawa, Yoichi M. Ito, Norihiro Sato, Ichiro Kusumi
Journal of Clinical Psychiatry, 83, 3, 21m14099, Physicians Postgraduate Press, Inc, Mar. 2022, [Peer-reviewed]
English, Scientific journal

The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression
Shuhei Ishikawa, Ryodai Yamamura, Naoki Hashimoto, Ryo Okubo, Ryo Sawagashira, Yoichi M. Ito, Norihiro Sato, Ichiro Kusumi
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 113, 110453, 110453, Elsevier BV, Oct. 2021, [Peer-reviewed], [International Magazine]
English, Scientific journal, There have been concerns that antipsychotics increase the incidence of hyperglycemic progression. Many factors have been suggested to contribute to the risk of antipsychotic-induced hyperglycemic progression, including the type, daily dose, and number of antipsychotics; however, few studies have examined these relationships. This study aimed to examine the affect of antipsychotic treatment-associated factors on hyperglycemic progression, after adjustment for the affect of background factors suggested to be associated with hyperglycemic progression. This was a nationwide, multicenter, prospective cohort study examining the incidence of hyperglycemic progression during a 12 mo period following the initiation of newly prescribed antipsychotic medication. Demographic data, medication history, and blood test values were collected from 631 study participants with normal blood glucose levels at baseline for 12 mo. The primary endpoint (incidence of hyperglycemic progression) was defined as progression from normal to prediabetic or probable diabetic status, and was evaluated based on the Japanese monitoring guidance in patients with schizophrenia. To further examine the affect of antipsychotics on glucose metabolism over time, we examined changes in HbA1c levels 3, 6, and 12 mo after the initiation of treatment with each antipsychotic. We found that treatment with zotepine and clozapine was associated with a significantly high incidence of hyperglycemic progression. Furthermore, changes in HbA1c levels 6 mo after the initiation of zotepine treatment were significantly higher than those following blonanserin and haloperidol treatments. In contrast, there was no significant difference in the change in total cholesterol, triglycerides, HDL cholesterol, and BMI during the same period. Moreover, the "daily dose" and "number" of antipsychotics did not show an association with the incidence of hyperglycemic progression. However, in a post hoc analysis in which the antipsychotics were divided into two groups according to the strength of blockade of H1, M1, M3, and 5-HT2C receptors, the incidence of hyperglycemic progression was higher in the medium- and high-daily dose groups than in the low-daily dose group in the antipsychotic group with strong blockade of these receptors. Our study indicated that the type of antipsychotic had a greater affect on the incidence of hyperglycemic progression than the daily dose of antipsychotics or their number. Among these, zotepine was most likely to increase the incidence of hyperglycemic progression, suggesting the need for caution when these antipsychotics are prescribed.

Lipid and energy metabolism of the gut microbiota is associated with the response to probiotic Bifidobacterium breve strain for anxiety and depressive symptoms in schizophrenia
Ryodai Yamamura, Ryo Okubo, Noriko Katsumata, Toshitaka Odamaki, Naoki Hashimoto, Ichiro Kusumi, Jinzhong Xiao, Yutaka J Matsuoka
Journal of Personalized Medicine, 11, 10, 987, 987, MDPI AG, Sep. 2021, [Peer-reviewed], [Lead author]
English, Scientific journal, A recent meta-analysis found that probiotics have moderate-to-large beneficial effects on depressive symptoms in patients with psychiatric disorders. However, it remains unclear how the baseline gut microbiota before probiotic administration influences the host’s response to probiotics. Therefore, we aimed to determine whether the predicted functional profile of the gut microbiota influences the effectiveness of probiotic treatment in patients with schizophrenia. A total of 29 patients with schizophrenia consumed Bifidobacterium breve A-1 (synonym B. breve MCC1274) for 4 weeks. We considered patients who showed a 25% or more reduction in the Hospital Anxiety and Depression Scale total score at 4 weeks from baseline to be “responders” and those who did not to be “non-responders”. We predicted the gut microbial functional genes based on 16S rRNA gene sequences and applied the linear discriminant analysis effect size method to determine the gut microbial functional genes most likely to explain the differences between responders and non-responders at baseline. The results showed that lipid and energy metabolism was elevated at baseline in responders (n = 12) compared to non-responders (n = 17). These findings highlight the importance of assessing the gut microbial functional genes at baseline before probiotic therapy initiation in patients with psychiatric disorders.

Perilla Oil and Bifidobacterium for Alleviating Fear of Cancer Recurrence in Breast Cancer Survivors: Study Protocol for a Three-Arm Phase II Randomized Controlled Study (POB Study)
Yohei Sasaki, Mina Honyashiki, Takayuki Kinoshita, Akira Matsui, Ayako Nakashoji, Takuma Inagawa, Satoru Ikezawa, Naoki Yoshimura, Ryodai Yamamura, Mizuki Amano, Yui Tomo, Hisateru Tachimori, Yutaka J. Matsuoka, Ryo Okubo
Methods and Protocols, 4, 3, 46, 46, MDPI AG, 06 Jul. 2021, [Peer-reviewed]
English, Scientific journal, The fear of cancer recurrence (FCR) is the most common and most severe unmet need among cancer survivors. Safe treatments for the FCR that are easily disseminated are greatly needed. Our primary aim is a preliminary evaluation of the efficacy and effect size of perilla oil, which is rich in omega-3 fatty acids, and Bifidobacterium, a probiotic, on FCR in breast cancer survivors after the completion of chemotherapy. This study has been planned as an exploratory clinical study (phase II) and will be conducted as a three-arm, 12-week parallel group, masked-rater randomized controlled trial. Fifteen participants will be randomized with 1:1:1 allocation to receive Bifidobacterium plus perilla oil, Bifidobacterium alone, or no intervention (control). Interventions will end within 12 weeks after the random allocation of each participant. The participants will be outpatients with invasive breast cancer aged 20 years or older whose chemotherapy was completed at least 6 months before registration; hormone therapy may be ongoing. The primary outcome will be severity of FCR at 12 weeks assessed by masked raters using the 4-item Concerns about Recurrence Scale concerning overall fear of recurrence. The study protocol for the current study is registered in the Japan Registry of Clinical Trials (jRCTs031200029).

Lower human defensin 5 in elderly people compared to middle-aged is associated with differences in the intestinal microbiota composition: the DOSANCO Health Study
Yu Shimizu, Kiminori Nakamura, Mani Kikuchi, Shigekazu Ukawa, Koshi Nakamura, Emiko Okada, Akihiro Imae, Takafumi Nakagawa, Ryodai Yamamura, Akiko Tamakoshi, Tokiyoshi Ayabe
GeroScience, 44, 2, 997, 1009, Springer Science and Business Media LLC, 08 Jun. 2021, [Peer-reviewed]
English, Scientific journal, Abstract

Recently, aging is considered a risk factor for various diseases. Although changes in the intestinal microbiota along with aging are thought to associate with the increased disease risk, mechanisms that cause age-related transition of the intestinal microbiota remain unknown. This study aims to clarify relationships between the amount of human defensin 5 (HD5), a Paneth cell α-defensin, which is known to regulate the intestinal microbiota, and age-related differences of the intestinal microbiota composition. Fecal samples from 196 healthy Japanese (35 to 81 years old) were collected and measured HD5 concentration. HD5 concentration in the elderly group (age > 70 years old) was significantly lower than the middle-aged group (age ≤ 70 years old). Furthermore, individual age was negatively correlated with HD5 concentration (r =  − 0.307, p < 0.001). In β-diversity, the intestinal microbiota of the elderly showed a significantly different composition compared to the middle-aged. At the genus level, relative abundance of Collinsella, Alistipes, Peptococcaceae; unassigned, Lactobacillus, Lactococcus, Weissella, Christensenellaceae R-7 group, Megasphaera, and [Eubacterium] eligens group was significantly higher, and Lachnospiraceae; unassigned, Blautia, Anaerostipes, Fusicatenibacter, Dorea, and Faecalibacterium was significantly lower in the elderly compared to the middle-aged. In addition, HD5 concentration was negatively correlated with Alistipes, Peptococcaceae; unassigned, and Christensenellaceae R-7 group and positively correlated with Lachnospiraceae; unassigned and Dorea. These results provide novel insights into the immunosenescence of enteric innate immunity, indicating low HD5 is suggested to contribute to the age-related differences in the intestinal microbiota and may relate to increased risk of diseases in elderly people.

Fecal short-chain fatty acids and obesity in a community-based Japanese population: The DOSANCO Health Study
Ryodai Yamamura, Koshi Nakamura, Shigekazu Ukawa, Emiko Okada, Takafumi Nakagawa, Akihiro Imae, Tadao Kunihiro, Takashi Kimura, Takumi Hirata, Akiko Tamakoshi
Obesity Research & Clinical Practice, 15, 4, 345, 350, Elsevier BV, Jun. 2021, [Peer-reviewed], [Lead author]
Scientific journal

Tiny Drosophila makes giant strides in cancer research
Ryodai Yamamura, Takako Ooshio, Masahiro Sonoshita
Cancer Science, 112, 2, 505, 514, Wiley, 05 Jan. 2021, [Peer-reviewed], [Lead author], [International Magazine]
English, Scientific journal, Cancer burden has been increasing worldwide, making cancer the second leading cause of death in the world. Over the past decades, various experimental models have provided important insights into the nature of cancer. Among them, the fruit fly Drosophila as a whole-animal toolkit has made a decisive contribution to our understanding of fundamental mechanisms of cancer development including loss of cell polarity. In recent years, scalable Drosophila platforms have proven useful also in developing anti-cancer regimens that are effective not only in mammalian models but also in patients. Here, we review studies using Drosophila as a tool to advance cancer study by complementing other traditional research systems.

ヒト便試料の保存条件とメタボローム変動のNMR解析(Impact of sample storage conditions on NMR-based human fecal metabolomics)
宋 子豪, 包 克非, 北田 直也, 清水 由宇, 菊池 摩仁, 熊木 康裕, 大西 裕季, 塚本 卓, 菊川 峰志, 出村 誠, 中村 公則, 綾部 時芳, 山村 凌大, 中村 幸志, 玉腰 暁子, 相沢 智康
腸内細菌学雑誌, 34, 2, 148, 148, (公財)腸内細菌学会, Apr. 2020
English

Associations of gut microbiota, dietary intake, and serum short-chain fatty acids with fecal short-chain fatty acids.
Ryodai Yamamura, Koshi Nakamura, Naoya Kitada, Tomoyasu Aizawa, Yu Shimizu, Kiminori Nakamura, Tokiyoshi Ayabe, Takashi Kimura, Akiko Tamakoshi
Bioscience of microbiota, food and health, 39, 1, 11, 17, 2020, [Peer-reviewed], [Lead author], [Domestic magazines]
English, Scientific journal, In recent years, short-chain fatty acids (SCFAs) have been reported to play an important role in maintaining human health. Fecal SCFA concentrations correlate well with colonic SCFA status and gut microbiota composition. However, the associations with the gut microbiota functional pathway, dietary intake, blood SCFAs, and fecal SCFAs remain uncertain. To clarify these relationships, we collected fecal samples, blood samples, and dietary habit data from 12 healthy adults aged 22-51 years. The relative abundance of several SCFA-producing bacteria, gut microbiota diversity, and functional pathways related to SCFA biosynthesis were positively associated with fecal SCFAs even after adjusting for age and sex. Furthermore, fecal acetate was likely to be positively associated with serum acetate. By contrast, dietary intake was not associated with fecal SCFAs. Overall, the present study highlights the potential usefulness of fecal SCFAs as an indicator of the gut microbiota ecosystem and dynamics of SCFAs in the human body.

Associations of gut microbiota, dietary intake, and serum SCFAs with fecal SCFAs
YAMAMURA Ryodai, NAKAMURA Koshi, NAKAMURA Koshi, KITADA Naoya, AIZAWA Tomoyasu, SHIMIZU Yu, NAKAMURA Kiminori, AYABE Tokiyoshi, KIMURA Takashi, TAMAKOSHI Akiko, 日本細菌学雑誌(Web), 75, 1, 2020

Association between archaea and obesity in a general Japanese population: The DOSANCO Health Study
山村凌大, 鵜川重和, 中村幸志, 木村尚史, 中川貴史, 今江章宏, 國弘忠生, 朴鐘旭, MOHSEN Attayeb, 川島和, 清水由宇, 中村公則, 綾部時芳, 玉腰暁子, 腸内細菌学雑誌, 34, 2, 2020

Association between lean, obesity and gut microbiota in a general Japanese population: The DOSANCO Health Study
木村尚史, 山村凌大, 檜森亮吾, 鵜川重和, 中村幸志, 中川貴史, 今江章宏, 國弘忠生, 朴鐘旭, MOHSEN Attayeb, 川島和, 清水由宇, 中村公則, 綾部時芳, 玉腰暁子, 腸内細菌学雑誌, 34, 2, 2020

血中短鎖脂肪酸と肥満との関連
山村凌大, CHEN Zhen, WU Yue, GAO Zijun, HUI Shu-Ping, 千葉仁志, 千葉仁志, 中川貴史, 鵜川重和, 鵜川重和, 中村幸志, 玉腰暁子, JSBMS Letters, 43, Supplement, 2018

Development of novel pancreatic ductal adenocarcinoma drugs targeting GPCRs by leveraging Drosophila　　　　　　　　　　　　　　　
Taiga Hirata, Ryodai Yamamura, Masahiro Sonoshita
Cell Symposia: Chemical biology in drugging the undrugged, 03 Dec. 2024, English, Poster presentation
02 Dec. 2024 - 04 Dec. 2024

潰瘍性大腸炎患者に特徴的な便中代謝物質プロファイル　　　　　　　　　　　　　　　
青山慶哉, 山村凌大, 野村朝子, 福島新弥, 桂田武彦, 福田真嗣, 園下将大, 坂本直哉
第32回日本消化器関連学会週間 JDDW2024, 31 Oct. 2024, English, Poster presentation
31 Oct. 2024 - 03 Nov. 2024

特発性大腿骨頭壊死症における腸内細菌叢の解析研究　　　　　　　　　　　　　　　
有田 皓介, 清水 智弘, 山村凌大, 横田隼一, 石津 帆高, 高橋 大介, 岩崎 倫政
第39回日本整形外科学会基礎学術集会, 17 Oct. 2024, Japanese, Oral presentation
17 Oct. 2024 - 18 Oct. 2024

特発性大腿骨頭壊死症における腸内細菌叢の解析研究　　　　　　　　　　　　　　　
有田 皓介, 清水 智弘, 山村凌大, 横田隼一, 石津 帆高, 高橋 大介, 岩崎 倫政
第73回東日本整形災害外科学会, 27 Sep. 2024, Japanese, Oral presentation
27 Sep. 2024 - 28 Sep. 2024

Distinctive fecal metabolite profiles in patients with ulcerative colitis　　　　　　　　　　　　　　　
Keiya Aoyama, Ryodai Yamamura, Asako Nomura, Shinya Fukushima, Takehiko Katsurada, Shinji Fukuda, Masahiro Sonoshita, Naoya Sakamoto
The 37th Congress of the Pan-Pacific Surgical Association, 17 May 2024, English, Oral presentation
16 May 2024 - 17 May 2024

Revealing the pathogenic impact arising from the interactions between pancreatic cancer cells and its associating extracellular matrix　　　　　　　　　　　　　　　
Soichiro Hata, Seiichiro Ishihara, Ryodai Yamamura, Hisashi Haga, Masahiro Sonoshita
フォトエキサイトニクス研究拠点 第６回研究会, 27 Mar. 2024, English, Poster presentation
27 Mar. 2024

Revealing the pathogenic impact arising from the interactions between pancreatic cancer cells and its associating extracellular matrix　　　　　　　　　　　　　　　
Soichiro Hata, Seiichiro Ishihara, Ryodai Yamamura, Hisashi Haga, Masahiro Sonoshita
Serendipity Symposium 2024, 12 Mar. 2024, English, Poster presentation
10 Mar. 2024 - 13 Mar. 2024

Dysbiosis of the gut microbiota and decreased fecal levels of short-chain fatty acid in patients with ulcerative colitis: A hospital-based case-control study　　　　　　　　　　　　　　　
Ryodai Yamamura, Takehiko Katsurada
19th Congress of European Crohn's and Colitis Organisation, 22 Feb. 2024, English, Poster presentation
21 Feb. 2024 - 24 Feb. 2024

Developing novel therapeutics for bladder cancer leveraging Drosophila models　　　　　　　　　　　　　　　
Takuya Moriguchi, Ryodai Yamamura, Masahiro Sonoshita, Nobuo Shinohara
European Society for Medical Oncology (ESMO) Congress 2023, 22 Oct. 2023, English, Poster presentation
20 Oct. 2023 - 24 Oct. 2023

Developing novel therapeutics for oral cancer leveraging Drosophila　　　　　　　　　　　　　　　
Taku Kimura, Ryodai Yamamura, Yoshimasa Kitagawa, Masahiro Sonoshita
105th American Association of Oral and Maxillofacial Surgeons, 21 Sep. 2023, English, Poster presentation
17 Sep. 2023 - 24 Sep. 2023

Utilizing Drosophila to elucidate the role of the microbiome in pancreatic tumorigenesis aiming for drug discovery　　　　　　　　　　　　　　　
Ryodai Yamamura
第12回 Top Runners in TRS, 22 Sep. 2023, Japanese, Public discourse
[Invited]

腸内細菌由来成分を活用した新規膵がん治療法の創出　　　　　　　　　　　　　　　
山村凌大
理化学研究所 生命機能科学研究センター 栄養応答研究チーム セミナー, 14 Jul. 2023, Japanese, Public discourse
14 Jul. 2023, [Invited]

The association between cognitive impairment and the gut microbiota in schizophrenia patients　　　　　　　　　　　　　　　
大久保亮, 山村凌大
第27回腸内細菌学会学術集会, 28 Jun. 2023, Public symposium
27 Jun. 2023 - 28 Jun. 2023

Shorter sleep time relates to lower human defensin 5 secretion and compositional disturbance of the intestinal microbiota accompanied by decreased short-chain fatty acid production　　　　　　　　　　　　　　　
清水由宇, 山村凌大, 横井友樹, 綾部時芳, 鵜川重和, 中村幸志, 岡田恵美子, 今江章宏, 中川貴史, 玉腰暁子, 中村公則
第27回腸内細菌学会学術集会, 28 Jun. 2023, Public symposium
27 Jun. 2023 - 28 Jun. 2023

Developing a novel therapeutic strategy for PDAC utilizing the gut microbial metabolites　　　　　　　　　　　　　　　
Ryodai Yamamura
金沢大学がん進展制御研究所 令和４年度共同利用・共同研究拠点研究成果報告会, 15 Feb. 2023, Japanese, Invited oral presentation
15 Feb. 2023 - 15 Feb. 2023, [Invited]

腸内細菌由来成分を活用した新規膵がん治療法の創出　　　　　　　　　　　　　　　
山村凌大
金沢大学がん進展制御研究所 腫瘍遺伝学研究分野 セミナー, 24 Nov. 2022, Japanese, Public discourse
[Invited]

Dysbiosis of the gut microbiota and decreased fecal levels of short-chain fatty acid in patients with ulcerative colitis: A hospital-based case-control study　　　　　　　　　　　　　　　
Ryodai Yamamura
9th World Congress on Targeting Microbiota 2022, 20 Oct. 2022, English, Poster presentation
19 Oct. 2022 - 21 Oct. 2022

統合失調症患者に対するプロバイオティクスの治療効果に腸内細菌の機能遺伝子プロファイルが及ぼす影響　　　　　　　　　　　　　　　
山村凌大, 大久保亮, 勝又紀子, 小田巻俊孝, 清水金忠
第26回腸内細菌学会学術集会, 07 Jul. 2022, Japanese, Poster presentation
07 Jul. 2022 - 08 Jul. 2022

潰瘍性⼤腸炎患者における腸内細菌叢の破綻と糞便中代謝産物の変動　　　　　　　　　　　　　　　
山村凌大
第４回COI学術交流会, 06 Feb. 2022, Japanese, Poster presentation
06 Feb. 2022 - 07 Feb. 2022

Dysbiosis of the gut microbiota and decreased fecal short-chain fatty acid levels in patients with ulcerative colitis: A hospital-based case-control study　　　　　　　　　　　　　　　
Ryodai Yamamura, Takumi Hirata, Takehiko Katsurada, Tomohiro Shimizu, Daisuke Takahashi, Tomoyasu Aizawa, Eiji Kondo, Norimasa Iwasaki, Naoya Sakamoto, Akiko Tamakoshi
8th World Congress on Targeting Microbiota 2021, 20 Oct. 2021, English, Poster presentation
20 Oct. 2021 - 22 Oct. 2021

腸内細菌およびその代謝産物が潰瘍性大腸炎の病態に及ぼす影響の解明と それに基づく新規潰瘍性大腸炎治療法の開発　　　　　　　　　　　　　　　
山村 凌大, 園下 将大, 玉腰 暁子, 坂本 直哉, 桂田 武彦, 小田切 信介, 福島 新弥
第7回北大・部局横断シンポジウム, 01 Oct. 2021, Japanese, Poster presentation
01 Oct. 2021 - 01 Oct. 2021

腸内細菌が産生する短鎖脂肪酸の糞便中濃度と糞便pHとの関連　　　　　　　　　　　　　　　
山村 凌大, 國弘 忠生, 中川 貴史, 鵜川 重和, 中村 幸志, 玉腰 暁子
第6回 北大・部局横断シンポジウム, 19 Oct. 2020, Poster presentation
19 Oct. 2020 - 19 Oct. 2020

Impact of sample storage conditions on NMR-based human fecal metabolomics　　　　　　　　　　　　　　　
宋 子豪, 包 克非, 北田 直也, 清水 由宇, 菊池 摩仁, 熊木 康裕, 大西 裕季, 塚本 卓, 菊川 峰志, 出村 誠, 中村 公則, 綾部 時芳, 山村 凌大, 中村 幸志, 玉腰 暁子, 相沢 智康
第24回腸内細菌学会学術集会, 11 Jun. 2020, Poster presentation
11 Jun. 2020 - 12 Jun. 2020

日本人地域一般住民における痩せ・肥満と腸内細菌叢との関連：The DOSANCO Health Study　　　　　　　　　　　　　　　
木村 尚史, 山村 凌大, 檜森 亮吾, 鵜川 重和, 中村 幸志, 中川 貴史, 今江 章宏, 國弘 忠生, 朴 鐘旭, Attayeb Mohsen, 川島 和, 清水 由宇, 中村 公則, 綾部 時芳, 玉腰 暁子
第24回腸内細菌学会学術集会, 11 Jun. 2020, Japanese, Poster presentation

日本人地域一般住民におけるアーキアと肥満との関連：The DOSANCO Health Study　　　　　　　　　　　　　　　
山村 凌大, 鵜川 重和, 中村 幸志, 木村 尚史, 中川 貴史, 今江 章宏, 國弘 忠生, 朴 鐘旭, Attayeb Mohsen, 川島 和, 清水 由宇, 中村 公則, 綾部 時芳, 玉腰 暁子
第24回腸内細菌学会学術集会, 11 Jun. 2020, Japanese, Poster presentation

地域在住高齢者の社会的孤立と痩せとの関連の検討　　　　　　　　　　　　　　　
加藤 利佳, 木村 尚史, 高林 早枝香, 篠原 尚子, 山村 凌大, 玉腰 暁子
第30回日本疫学会学術総会, 22 Feb. 2020, Japanese, Poster presentation

Associations of gut microbiota, dietary intake, and serum short-chain fatty acids with fecal short-chain fatty acids　　　　　　　　　　　　　　　
Ryodai Yamamura, Koshi Nakamura, Naoya Kitada, Tomoyasu Aizawa, Yu Shimizu, Kiminori Nakamura, Tokiyoshi Ayabe, Takashi Kimura, Akiko Tamakoshi
第93回日本細菌学会総会, 19 Feb. 2020, Japanese, Poster presentation

Relationship between frailty and finger tapping parameters among older people in Hokkaido: in dominant hand and non-dominant hand　　　　　　　　　　　　　　　
石 蕊, 趙 文静, 木村 尚史, 山村 凌大, 高林 早枝香, 篠原 尚子, 玉腰 暁子
第3回新しい運動機能研究会, Oct. 2019, Japanese, Poster presentation

腸内細菌叢、短鎖脂肪酸とヒトの健康との関連　　　　　　　　　　　　　　　
山村 凌大
2019年度第3回消化器内科セミナー, 16 Jul. 2019, Japanese, Public discourse
[Invited]

Fecal concentrations of short chain fatty acids and human obesity　　　　　　　　　　　　　　　
Ryodai Yamamura, Tadao Kunihiro, Takafumi Nakagawa, Shigekazu Ukawa, Koshi Nakamura, Akiko Tamakoshi
Cell Symposia: Metabolites as Signaling Molecules, 11 Dec. 2018, English, Poster presentation

腸内細菌が産生する短鎖脂肪酸の糞便中濃度と糞便pHとの関連　　　　　　　　　　　　　　　
⼭村 凌⼤, 國弘 忠⽣, 中川 貴史, 鵜川 重和, 中村 幸志, 玉腰 暁子
第1回COI学会, 26 Oct. 2018, Japanese, Poster presentation

Optimized Sample Storage Strategy for Metabolic Profiling of Human Feces　　　　　　　　　　　　　　　
包 克非, 北田 直也, 稲村 勇雅, 熊木 康裕, 大西 裕季, 塚本 卓, 菊川 峰志, 出村 誠, 中村 公則, 綾部 時芳, 中村 幸志, 玉腰 暁子, 相沢 智康, 山野 めぐみ, 山村 凌大
第57回NMR検討会, 20 Sep. 2018, Japanese, Poster presentation

Serum short chain fatty acid and obesity　　　　　　　　　　　　　　　
山村 凌大, 陳 震, 呉 玥, 高 紫君, 惠 淑萍, 千葉 仁志, 中川 貴史, 鵜川 重和, 中村 幸志, 玉腰 暁子
第43回日本医用マススペクトル学会, 06 Sep. 2018, Japanese, Poster presentation

Development of short-chain fatty acid supplements and the gut microbiome diagnostic toilet　　　　　　　　　　　　　　　
山村 凌大, 山崎 聖司, 井上 久美
Japan Science and Technology Agency Fair 2018, 31 Aug. 2018, Japanese, Invited oral presentation
30 Aug. 2018 - 31 Aug. 2018, [Invited]

腸内フローラ判定トイレと改善サプリの開発　　　　　　　　　　　　　　　
山村 凌大
平成30年度COIプログラムサイトビジット, 17 Jul. 2018, Japanese, Others

腸内フローラ判定トイレと改善サプリの開発　　　　　　　　　　　　　　　
山崎 聖司, 井上 久美, 山村 凌大
COI2021第4回ワークショップ, 05 Jun. 2018, Japanese, Public symposium

DOSANCO Health Study (Dynamics of lifestyle and Neighborhood Community on Health Study) -概要と腸内細菌叢研究-　　　　　　　　　　　　　　　
山村 凌大
第6回北海道疫学交流会, 16 Jan. 2018, Japanese, Public discourse

腸内フローラ判定トイレと改善サプリの開発　　　　　　　　　　　　　　　
山崎 聖司, 井上 久美, 山村 凌大
第3回COI2021会議, 21 Nov. 2017, Japanese, Oral presentation

腸内フローラ判定トイレと改善サプリの開発　　　　　　　　　　　　　　　
山崎 聖司, 井上 久美, 山村 凌大
第二回COI若手連携研究会, 05 Nov. 2017, Japanese, Public symposium

健康増進に寄与する腸内細菌遺伝子・産生物質の同定および応用製品開発　　　　　　　　　　　　　　　
山村 凌大, 山崎 聖司
第二回COI若手連携研究会, 04 Nov. 2017, Japanese, Public symposium

健康増進に寄与する腸内細菌遺伝子・産生物質の同定および応用製品開発　　　　　　　　　　　　　　　
山村 凌大, 山崎 聖司
COI2021第2回ワークショップ, 15 Sep. 2017, Japanese, Public symposium

『短鎖脂肪酸』が操る人々の健康　　　　　　　　　　　　　　　
山村 凌大
COI2021第1回ワークショップ, 23 Jun. 2017, Japanese, Public symposium

女子看護学生のライフスタイル、栄養状態、排便状況の関連　　　　　　　　　　　　　　　
山村 凌大, 金安 顕子, 田中 穂乃佳, 西川 明里, 山内 太郎
日本生理人類学会健康栄養科学研究部会第1回研究会, 19 Dec. 2015, Japanese, Oral presentation

女子看護学生の身体特性、生活習慣、健康状態の関連　　　　　　　　　　　　　　　
山村 凌大, 金安 顕子, 田中 穂乃佳, 西川 明里, 山内 太郎
第30回日本国際保健医療学会, 22 Nov. 2015, Japanese, Poster presentation

The Relationships among Physical Characteristics, Lifestyle and Health Status in Female Nursing Students　　　　　　　　　　　　　　　
Ryodai Yamamura, Akiko Kaneyasu, Honoka Tanaka, Akari Nishikawa, Taro Yamauchi
The 12th International Congress of Physiological Anthropology, 28 Oct. 2015, English, Poster presentation

中国東北部の都市部・農村部に暮らす小学生の肥満に影響する因子の検討　　　　　　　　　　　　　　　
カク明, 山村 凌大, Han Wei, Jia Lihong, 山内 太郎
第22回未病システム学会, 11 Oct. 2015, Japanese, Poster presentation

女子大生の食習慣，身体活動と排便状況：便秘予備群のリスク　　　　　　　　　　　　　　　
山村 凌大, 磯野 晃照, 櫻井 ちひろ, 山内 太郎
第22回未病システム学会, 11 Oct. 2015, Japanese, Poster presentation

Lifestyle and bowel habits in female college students: Risk of the pre-constipation group　　　　　　　　　　　　　　　
Ryodai Yamamura, Akiteru Isono, Chihiro Sakurai, Taro Yamauchi
The Second FHS International Conference, 03 Jul. 2015, English, Poster presentation

女子大生の生活習慣と排便状況 –便秘予備群のリスク–　　　　　　　　　　　　　　　
山村 凌大, 磯野 晃照, 櫻井 ちひろ, 山内 太郎
第72回日本生理人類学会, 30 May 2015, Japanese, Poster presentation

Lifestyle and body weight changes over two years in female nursing student　　　　　　　　　　　　　　　
Ryodai Yamamura, Akane Kato, Natsumi Hirai, Saki Maeda, Taro Yamauchi
12th Asian Congress of Nutrition, 16 May 2015, English, Poster presentation

日本人の健康情報に対する関心：WHO疫学週報トピックスの利用状況解析　　　　　　　　　　　　　　　
山村 凌大, 山内 太郎, 安藤 啓司, 宇佐美 眞, 中澤 港
第78回日本民族衛生学会, Nov. 2013, Japanese, Poster presentation

社会学　　　　　　　　　　　　　　　
北海道医療センター附属札幌看護学校
Aug. 2021 - Present

公衆衛生論　　　　　　　　　　　　　　　
北海道医療センター附属札幌看護学校
Apr. 2018 - Present

Jan. 2022 - Present
Japanese Society of Public Health　　　　　　　　　　　　　　　

Jan. 2022 - Present
Japan Epidemiological Association　　　　　　　　　　　　　　　

Dec. 2021 - Present
Molecular Biology Society of Japan　　　　　　　　　　　　　　　

Dec. 2021 - Present
Japanese Cancer Association　　　　　　　　　　　　　　　

腸内細菌由来成分を活用した新規膵がん治療法の創出　　　　　　　　　　　　　　　
2023年度 医学系研究助成
Aug. 2023 - Mar. 2028
山村凌大
公益財団法人 武田科学振興財団, Principal investigator

腸内細菌由来成分を活用した新規膵がん治療法の創出　　　　　　　　　　　　　　　
2024年度 創成はばたく次世代研究助成事業
Jul. 2024 - Mar. 2026
北海道大学, 北海道大学, Principal investigator

腸内細菌由来成分を活用した新規膵がん治療法の創出　　　　　　　　　　　　　　　
科学研究費助成事業 若手研究
Apr. 2024 - Mar. 2026
日本学術振興会, 北海道大学, Principal investigator

腸内細菌由来成分を活用した新規膵がん治療法の創出　　　　　　　　　　　　　　　
JCA-KFCR 若手研究助成
Sep. 2024 - Aug. 2025
日本癌学会・小林がん学術振興会, 北海道大学, Principal investigator

腸内細菌叢が膵がんの病態に与える影響の解明　　　　　　　　　　　　　　　
令和6年度 金沢大学がん進展制御研究所共同研究
Apr. 2024 - Mar. 2025
山村凌大、園下将大
金沢大学がん進展制御研究所, 北海道大学, Principal investigator

腸内細菌由来成分を活用した新規膵がん治療法の創出　　　　　　　　　　　　　　　
第37回ノバルティス研究奨励金
Apr. 2024 - Mar. 2025
公益財団法人 ノバルティス科学振興財団, 北海道大学, Principal investigator

ショウジョウバエを活用した新規膀胱がん治療法の開発　　　　　　　　　　　　　　　
2024年度 日本新薬公募研究助成
Apr. 2024 - Mar. 2025
北海道大学, Principal investigator

腸内細菌由来成分を活用した新規膵がん治療法の創出　　　　　　　　　　　　　　　
第32回研究奨励助成
Apr. 2024 - Mar. 2025
公益財団法人 小野医学研究財団, 北海道大学, Principal investigator

Development of Oral Cancer Prevention Methods Based on Analysis of Oral Bacterial Flora and Inflammatory Cytokines in Saliva
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
Apr. 2022 - Mar. 2025
大賀 則孝, 北川 善政, 坂田 健一郎, 山村 凌大, 佐藤 淳, 園下 将大, 長谷部 晃
Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C), Hokkaido University, Coinvestigator, 22K10163

腸内細菌由来成分を活用した新規膵がん治療法の創出　　　　　　　　　　　　　　　
第38回 研究助成
Sep. 2023 - Aug. 2024
山村凌大
公益財団法人 寿原記念財団, Principal investigator

ショウジョウバエと哺乳類実験系の連動による新規潰瘍性大腸炎治療法の開発　　　　　　　　　　　　　　　
令和５年度「創成若手研究加速支援事業」
Apr. 2023 - Mar. 2024
北海道大学, 北海道大学, Principal investigator

腸内細菌叢が膵がんの病態に与える影響の解明　　　　　　　　　　　　　　　
令和5年度 金沢大学がん進展制御研究所共同研究
Apr. 2023 - Mar. 2024
山村凌大、園下将大
金沢大学がん進展制御研究所, Principal investigator

腸内・口腔内・腫瘍内細菌が膵がんの病態に及ぼす影響の解明と新規膵がん治療法の開発　　　　　　　　　　　　　　　
Grants-in-Aid for Scientific Research
Apr. 2021 - Mar. 2024
Japan Society for the Promotion of Science, 若手研究, Hokkaido University, Principal investigator

腸内細菌叢が膵がんの病態に与える影響の解明　　　　　　　　　　　　　　　
令和4年度 金沢大学がん進展制御研究所共同研究
Apr. 2022 - Mar. 2023
山村凌大、園下将大
金沢大学がん進展制御研究所, Principal investigator

腸内細菌由来成分を活用した新規膵がん治療法の創出　　　　　　　　　　　　　　　
令和３年度調査研究助成金
Dec. 2021 - Nov. 2022
山村凌大、園下将大
公益財団法人鈴木謙三記念医科学応用研究財団, Principal investigator

膵がんの発症・病期進行・治療応答性・生活の質と相関する細菌叢バイオマーカーおよび新規治療法の創出　　　　　　　　　　　　　　　
センター・オブ・イノベーションプログラム 若手連携研究ファンド
Apr. 2021 - Mar. 2022
山村凌大, 山崎聖司, 大久保亮
科学技術振興機構, Principal investigator

腸内フローラ判定トイレと改善サプリの開発　　　　　　　　　　　　　　　
センター・オブ・イノベーションプログラム 若手連携研究ファンド
Apr. 2018 - Mar. 2019
山村 凌大, 山崎 聖司, 井上 久美
科学技術振興機構, 北海道大学, Principal investigator

未来の健康・医療・バイオ探求アカデミア　　　　　　　　　　　　　　　
27 Oct. 2024
Advisor
Others
一般社団法人Ezofrogs

北海道札幌北高等学校 職場訪問　　　　　　　　　　　　　　　
10 Jan. 2024
Advisor
Others

札幌市立向陵中学校 研究体験　　　　　　　　　　　　　　　
21 Aug. 2023
Advisor

北海道大学遺伝子病制御研究所 こども研究所　　　　　　　　　　　　　　　
30 Mar. 2023
Advisor

Apr. 2019 - Mar. 2020
中部奨学会 2019年度奨学生

Apr. 2018 - Mar. 2019
小島三司奨学金 平成30年度奨学生

Apr. 2016 - Mar. 2017
公益信託石津俊記念奨学基金 平成28年度奨学生

日本学生支援機構 第一種奨学金 平成27年度特に優れた業績による返還免除の認定